Publications

1. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 Aug 27 [Epub ahead of print]
   View PubMed
2. Wang F, Molina J, Satele D, Yin J, Lim VS, Adjei AA. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Invest New Drugs. 2019 Aug; 37 (4):658-665 Epub 2018 Oct 31
   View PubMed
3. Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ Jr. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019 Aug; 14 (8):1343-1353 Epub 2019 May 25
   View PubMed
4. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Aug; 37 (4):755-762 Epub 2019 June 06
   View PubMed
5. Luo YH, Luo L, Wampfler JA, Wang Y, Liu D, Chen YM, Adjei AA, Midthun DE, Yang P. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. Lancet Oncol. 2019 Aug; 20 (8):1098-1108 Epub 2019 June 26
   View PubMed
6. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019 Aug; 94 (8):1599-1622
   View PubMed
7. Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019 Jul; 14 (7):1172-1183 Epub 2019 May 22
   View PubMed
8. Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 Jun 28 Epub 2019 June 28
   View PubMed
9. Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019 Apr 29 [Epub ahead of print]
   View PubMed
10. Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, Lim VS, Kaufmann SH, Adjei A. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2019 Apr; 37 (2):307-314 Epub 2018 Aug 31
    View PubMed
11. Xie H, Adjei AA. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies. J Thorac Oncol. 2019 Mar; 14 (3):358-376 Epub 2018 Dec 30
    View PubMed
12. Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb; 42 (2):184-189
    View PubMed
13. Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019 Jan; 24 (1):96-102 Epub 2018 Nov 09
    View PubMed
14. Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, Stewart PW, Suissa S, Adjei AA, Akdis CA, Azoulay E, Bakker J, Ballas ZK, Bardin PG, Barreiro E, Bellomo R, Bernstein JA, Brusasco V, Buchman TG, Chokroverty S, Collop NA, Crapo JD, Fitzgerald DA, Hale L, Hart N, Herth FJ, Iwashyna TJ, Jenkins G, Kolb M, Marks GB, Mazzone P, Moorman JR, Murphy TM, Noah TL, Reynolds P, Riemann D, Russell RE, Sheikh A, Sotgiu G, Swenson ER, Szczesniak R, Szymusiak R, Teboul JL, Vincent JL. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Ann Am Thorac Soc. 2019 Jan; 16 (1):22-28
    View PubMed
15. Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018 Nov 23; 6 (1):129
    View PubMed
16. Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol. 2018 Nov; 13 (11):1625-1637 Epub 2018 Sept 04
    View PubMed
17. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 Nov; 13 (11):1655-1667 Epub 2018 Sept 25
    View PubMed
18. Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct; 7 (10):4932-4942 Epub 2018 Sept 02
    View PubMed
19. Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic BI, Wakelee HA. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2018 Sep; 82 (3):541-550 Epub 2018 July 20
    View PubMed
20. Goyal G, Kommalapati A, Bartley AC, Gunderson TM, Adjei AA, Go RS. Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer. 2018 Aug; 122:214-219 Epub 2018 June 19
    View PubMed
21. Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018 Apr 19; 3 (8)
    View PubMed
22. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
23. Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. Eur J Cancer. 2017 Nov; 86:186-196 Epub 2017 Oct 06
    View PubMed
24. Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017 Oct 20; 35 (30):3391-3400 Epub 2017 Aug 30
    View PubMed
25. Leventakos K, Peikert T, Midthun DE, Molina JR, Blackmon S, Nichols FC, Garces YI, Hallemeier CL, Murphy SJ, Vasmatzis G, Kratz SL, Holland WP, Thomas CF, Mullon JJ, Shen KR, Cassivi SD, Marks RS, Aubry MC, Adjei AA, Yang P, Allen MS, Edell ES, Wigle D, Mansfield AS. Management of Multifocal Lung Cancer: Results of a Survey. J Thorac Oncol. 2017 Sep; 12 (9):1398-1402 Epub 2017 June 03
    View PubMed
26. Anwar S, Tan W, Hong CC, Admane S, Dozier A, Siedlecki F, Whitworth A, DiRaddo AM, DePaolo D, Jacob SM, Ma WW, Miller A, Adjei AA, Dy GK. Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events. Cancers (Basel). 2017 Jun 26; 9 (7) Epub 2017 June 26
    View PubMed
27. Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR, Mayo Clinic, North Central Cancer Treatment Group. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol. 2017 Apr; 12 (4):697-703 Epub 2017 Jan 12
    View PubMed
28. Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 Feb; 22 (2):189-198 Epub 2017 Feb 10
    View PubMed
29. Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bozon V. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Feb; 35 (1):47-58 Epub 2016 Sept 21
    View PubMed
30. Soo RA, Adjei AA. Predicting clinical outcomes using proteomics in non–small cell lung cancer—the past, present, and future Journal of Thoracic Oncology. 2017; 12: (4)602-6.
    
31. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 Nov 20; 34 (33):3992-3999 Epub 2016 Sept 30
    View PubMed
32. Calvo E, Soria JC, Ma WW, Wang T, Bahleda R, Tolcher A, Gernhardt D, O'Connell J, Millham R, Giri N, Wick MJ, Adjei AA, Hidalgo M. A Phase I Clinical Trial and Independent Patient-derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clin Cancer Res. 2016 Oct 12;
    View PubMed
33. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 Aug; 11 (8):1246-1262
    View PubMed
34. Rosen LS, LoRusso P, Ma W, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs. 2016 Jul 16;
    View PubMed
35. Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clin Cancer Res. 2016 May 15; 22: (10)2368-76.
    View PubMed
36. Adjei AA, Arena S, Siravegna G, Mussolin B, Kearns JD, Wolff BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med.2016;8:(324)324ra14.
    
37. Desai A, Adjei AA. FGFR signaling as a target for lung cancer therapy. J Thoracic Oncol.2016;11:9-20.
    
38. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10: (10)1396-403.
    View PubMed
39. Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10 (7):1099-106
    View PubMed
40. Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist. 2015 Jun; 20: (6)660-73.
    View PubMed
41. Zhao Y, Adjei AA. New strategies to develop new medications for lung cancer and metastasis. Cancer Metastasis Rev. 2015 Jun; 34 (2):265-75
    View PubMed
42. Wang X, Adjei AA. Lung cancer and metastasis: new opportunities and challenges. Cancer Metastasis Rev. 2015 Jun; 34 (2):169-71
    View PubMed
43. Infante JR, Benhadji KA, Dy GK, Fetterly G, Ma W, Bendell J, Callies S, Adjei AA. Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2015 Apr; 33: (2)432-9.
    View PubMed
44. Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma W, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33: (1)159-68.
    View PubMed
45. Ngamphaiboon N, Dy GK, Ma W, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33: (1)225-32.
    View PubMed
46. Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10 (1):172-80
    View PubMed
47. Peters S, Adjei AA. Lung cancer. How much platinum-based chemotherapy is enough in NSCLC? Nat Rev Clin Oncol. 2015 Jan; 12: (1)8-10.
    View PubMed
48. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G Jr, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF Jr, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R 3rd, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD 3rd, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, et al, Shen H, Zhou B, Shi J. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23 (24):6616-33 Epub 2014 July 15
    View PubMed
49. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014 Sep; 40: (8)917-26.
    View PubMed
50. Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J, Adjei AA. A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer. 2014 Aug; 85 (2):245-50 Epub 2014 May 01
    View PubMed
51. Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. J Thorac Oncol. 2014 Aug; 9 (8):1146-53
    View PubMed
52. Adjei AA, Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S, Panel Members//ESMO. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014 Aug; 25: (8)1475-84.
    View PubMed
53. Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 2014 Jul; 40: (6)750-9.
    View PubMed
54. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014 Jul; 11: (7)385-400.
    View PubMed
55. Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, LoRusso PM. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest New Drugs. 2014 Jun; 32: (3)510-7.
    View PubMed
56. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014 Mar; 40: (2)300-6.
    View PubMed
57. Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014 Feb 4; 110 (3):602-8 Epub 2013 Nov 28
    View PubMed
58. Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Gannon J, Adjei AA, Adjei AA, Ramnath N. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9 (2):222-30
    View PubMed
59. Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014 Jan; 99(1):60-9. Epub 2013 Aug 30.
    View PubMed
60. Adjei AA, Voide C, Zimmermann S, Betticher DC, Meuli R, Prodham G, Giulieri S, Peters S. Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small cell lung cancer. J Thoracic Oncol.2014;9:(3)e24-6.
    
61. Zhao Y, Adjei AA. Targeting oncogenic drivers. Prog Tumor Res. 2014; 41:1-14.
    View PubMed
62. Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer. 2013 Dec; 82: (3)375-82.
    View PubMed
63. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013 Nov; 24 (10):1079-83
    View PubMed
64. Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31 (5):1201-6 Epub 2013 July 26
    View PubMed
65. Dy GK, Infante JR, Eckhardt SG, Novello S, Ma W, Jones SF, Huff A, Wang Q, Suttle AB, Ottesen LH, Adjei AA, Burris HA 3rd. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs. 2013 Aug; 31: (4)891-9.
    View PubMed
66. Infante JR, Novello S, Ma W, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31: (4)927-36.
    View PubMed
67. Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma W, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1; 19: (5)1232-43.
    View PubMed
68. Nwogu CE, Yendamuri S, Tan W, Kannisto E, Bogner P, Morrison C, Cheney R, Dexter E, Picone A, Hennon M, Hutson A, Reid M, Adjei A, Demmy TL. Lung cancer lymph node micrometastasis detection using real-time polymerase chain reaction: correlation with vascular endothelial growth factor expression. J Thorac Cardiovasc Surg. 2013 Mar; 145: (3)702-7; discussion 707-8.
    View PubMed
69. Adjei AA, Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R. A phase I trial of KX2-391, a novel non-ATP competetive substrate-pocket-directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs.;31()967-73.
    
70. Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol. 2013 Jan; 8 (1):79-88
    View PubMed
71. Adjei AA, Chow LQ, Jonker DI, Dy GK, Nicholas G, Fortin C, Patricia D, Belani CP, Gupta A, Park JS, Zhang S, Sbar EI, Laurie SA. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies. Cancer Chemother Pharmacol.;71()1273-85.
    
72. Adjei AA, Dy GK. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin.;63(249-79).
    
73. Adjei AA, Pennella E, Obasaju CK, Pohl G, Peltz G, Girvan AC, Winfree KB, Martinez B, Marciniak M, Walker MS, Stepanski E, Schwartzberg LS. Prospective observational comparison of clinical outcomes between African-American and Caucasian patients receiving second-line treatment with pemetrexed for advanced non-small cell lung cancer. Clin Lung Cancer.;14()721-35.
    
74. Adjei AA, Schmieder R, Puehler F, Neuhaus R, Kissel M, Miner JN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia.;15()1147-57.
    
75. Adjei AA. Preclinical and clinical studies with combinations f pemetrexdd and gemcitabine. Sem Oncol.2013;29:(6)30-34.
    
76. Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA, North Central Cancer Treatment Group. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012 Nov; 23 (11):2919-24 Epub 2012 July 10
    View PubMed
77. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 2012 Nov 1; 118 (21):5358-65 Epub 2012 Mar 20
    View PubMed
78. Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, Hua X, Ding F, Lu Y, James M, Ebben JD, Xu H, Adjei AA, Head K, Andrae JW, Tschannen MR, Jacob H, Pan J, Zhang Q, Van den Bergh F, Xiao H, Lo KC, Patel J, Richmond T, Watt MA, Albert T, Selzer R, Anderson M, Wang J, Wang Y, Starnes S, Yang P, You M. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 2012 Jul; 33(7):1270-6. Epub 2012 Apr 17
    View PubMed
79. Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol. 2012 May; 7 (5):919-22
    View PubMed
80. Adjei AA, Peters S. MET a promising anticancer therapeutic target. Nat Rev Clin Oncol.;9(6)314-26.
    
81. Ma W, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res. 2012 Apr 1; 18: (7)2048-55.
    View PubMed
82. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2012 Mar; 87 (3):277-83 Epub 2011 Dec 21
    View PubMed
83. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7 (2):419-26
    View PubMed
84. Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J Hepatol. 2012 Jan; 56: (1)176-83.
    View PubMed
85. Adjei AA, Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Camidge DR. A phase I/II study of erlotinib in combination with t-he anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol.;7(2)419-26.
    
86. Adjei AA, Peters S, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small lung cancer: (NSCLC) ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol.;7()56-64.
    
87. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96 (11):1619-26 Epub 2011 July 26
    View PubMed
88. Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI. A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. Cancer Invest. 2011 Nov; 29(9):617-25.
    View PubMed
89. Adjei AA, Sharma N. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol.;3(suppl 1)s37-50.
    
90. An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res. 2011 Oct 15; 17(20):6592-9. Epub 2011 Aug 31.
    View PubMed
91. Adjei AA, Lorusso PM, Jimeno A, Dy GK, Berlin JD, Leichman LP, Low J, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic soid tumors. Clin Cancer Res.;17(17)5774-82.
    
92. Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, DeMarzo A, Netto GJ, Dispenzieri A, Kyle RA, Rajkumar SV, Landgren O. High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. Am J Hematol. 2011 Jul; 86 (7):554-8 Epub 2011 June 14
    View PubMed
93. Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer. 2011 Jul; 12(4):212-7. Epub 2011 Apr 28.
    View PubMed
94. Adjei AA, Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Rapasky E, Dy GK. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol.;6(6)998-1005.
    
95. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011 Mar 15; 117 (6):1262-71 Epub 2010 Oct 19
    View PubMed
96. Adjei AA, Schwartz B, Garmey E. Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treament of advanced cancers. Oncologist.;16(6)788-99.
    
97. Dy GK, Hillman SL, Rowland KM, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA, North Central. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 2010 Dec 15; 116(24):5686-93.
    View PubMed
98. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010 Nov; 52 (5):1680-9
    View PubMed
99. Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int. 2010 Nov; 30 (10):1522-8 Epub 2010 Sept 08
    View PubMed
100. Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol. 2010 Oct; 21 (10):2040-4 Epub 2010 June 21
     View PubMed
101. Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol. 2010 Sep; 5 (9):1346-53
     View PubMed
102. Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. Am J Clin Oncol. 2010 Aug; 33 (4):353-7
     View PubMed
103. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene. 2010 Feb 25; 29 (8):1190-202 Epub 2009 Nov 23
     View PubMed
104. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1; 28 (4):614-9 Epub 2009 Oct 19
     View PubMed
105. Adjei AA, Bhaskarla A, Tang P, Mashtare T, Demmy T, Nwogu C, Reid M, Yendamuri S. Synchronous non small cell lung cancers should not be classified as stage IV - a Seer database analysis. J Surg Res.;158(2)173.
     
106. Adjei AA, Bhaskarla A, Tang PC, Mashtare T, Nwogu CE, Demmy TL, Reid ME, Yendamuri S. Analysis of second primary lung cancers in the SEER database. J Surg Res.;162(1)1-6.
     
107. Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Jan; 5 (1):3-9
     View PubMed
108. Wakelee H, Loo BW Jr, Kernstine KH, Putnam JB Jr, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara DR. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10: (6)395-404.
     View PubMed
109. Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, Garces YI, Soori GS, Adjei AA, Sloan JA. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4 (9):1075-82
     View PubMed
110. Adjei AA, Sangha R, Lara PN Jr, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. Cooperative research adventures endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer.;10(5)322-330.
     
111. Adjei AA, Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Ann Thorac Surg.;88(2)385-391.
     
112. Adjei AA, Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Ann Thorac Surg.;88(2)385-391.
     
113. Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009 Jun 15; 115 (12):2721-31
     View PubMed
114. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52. Epub 2008 Dec 24.
     View PubMed
115. Adjei AA, Dy GK. ging therapeutic targets in non-small cell lung cancer. Proc Am Thorac Soc.;6(2)218-222.
     
116. Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol. 2009 Apr; 4 (4):479-85
     View PubMed
117. Adjei AA, McShane LM, Hunsberger S. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res.;15(6)1898-1905.
     
118. Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res.;15(6)1866-1872.
     
119. Ma W, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009 Mar-Apr; 59: (2)111-37.
     View PubMed
120. Dy G, Hillman S, Rowland K, Molina J, Steen P, Wender D, Nair S, Mandrekar S, Schild S, Adjei A. A Front-Line "Window of Opportunity" Phase II Study of Sorafenib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - A North Central Cancer Treatment Group Study N0326. Cancer. 2009.
     
121. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008 Dec 1; 14 (23):7900-8
     View PubMed
122. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35 (5):530-44
     View PubMed
123. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 2008 Aug 1; 68(15):6145-53.
     View PubMed
124. Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J, Adjei AA. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro Oncol. 2008 Jun; 10(3):309-19. Epub 2008 Apr 29.
     View PubMed
125. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1; 26(13):2139-46. Epub 2008 Apr 07.
     View PubMed
126. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer. 2008 May; 60 (2):200-7 Epub 2007 Nov 28
     View PubMed
127. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May; 83 (5):584-94
     View PubMed
128. Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA, North Central Cancer Treatment Group. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer. 2008 Apr 15; 112(8):1772-9.
     View PubMed
129. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008 Apr; 7 (4):944-51
     View PubMed
130. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 2008 Apr; 47 (4):1211-22
     View PubMed
131. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008 Mar; 83 (3):355-67
     View PubMed
132. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008 Jan 15; 14(2):342-6.
     View PubMed
133. Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Cancer Chemother Pharmacol. 2008 Jan; 61(1):39-45. Epub 2007 Mar 20.
     View PubMed
134. Adjei AA, Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Shepherd F, Choy H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer.;9(1)9-15.
     
135. Adjei AA, Langer CJ, Wakelee H, Schiller J, Choy J, Shepherd F, Vokes EE, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer.;9(2)85-91.
     
136. Adjei AA, Dy GK. Systemic cancer therapy: evolution over the last 60 years. Cancer.;113()1857-1887.
     
137. Adjei AA. K-ras as a target for lung cancer therapy. J Thorac Oncol.;3(6; suppl 2)s160-163.
     
138. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Larson DR, Dispenzieri A, Melton LJ 3rd, Goldin LR, McMaster ML, Caporaso NE, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007 Dec; 82(12):1468-73.
     View PubMed
139. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem. 2007 Oct 12; 282 (41):29831-46 Epub 2007 Aug 13
     View PubMed
140. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007 Oct 01; 13 (19):5834-40
     View PubMed
141. Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res. 2007 Sep 15; 67 (18):8772-82
     View PubMed
142. Barton DL, Loprinzi CL, Atherton P, Raymond J, Shanafelt T, Hines S, Palmieri F, Rummans T, Adjei AA, Sloan J. Phase II Evaluation of Desipramine for the Treatment of Hot Flashes. Support Cancer Ther. 2007 Sep 1; 4(4):219-24.
     View PubMed
143. Schild SE, Bonner JA, Hillman S, Kozelsky TF, Vigliotti AP, Marks RS, Graham DL, Soori GS, Kugler JW, Tenglin RC, Wender DB, Adjei A. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol. 2007 Jul 20; 25 (21):3124-9
     View PubMed
144. Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA, North Central Cancer Treatment GroupThis study was conducted as a collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 2007 Jul 15; 110(2):363-8.
     View PubMed
145. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 2007 Jun 15; 13: (12)3611-6.
     View PubMed
146. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res. 2007 May 1; 13(9):2684-91.
     View PubMed
147. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94. Epub 2006 Nov 02.
     View PubMed
148. Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007 Feb 15; 13 (4):1140-8
     View PubMed
149. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2007 Feb; 59(2):207-15. Epub 2006 Jun 9
     View PubMed
150. Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 2007; 7:13. Epub 2007 Aug 17.
     View PubMed
151. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006 Oct 15; 12: (20 Pt 1)6087-93.
     View PubMed
152. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006 Oct; 130(4):1211-9.
     View PubMed
153. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol. 2006 Sep; 1(7):749-51.
     View PubMed
154. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep; 5 (9):2378-87
     View PubMed
155. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006 Aug 15; 107(4):781-92.
     View PubMed
156. Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Aug; 58 (2):165-72 Epub 2005 Nov 19
     View PubMed
157. Adjei AA. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res. 2006 Jul 15; 12 (14 Pt 2):4446s-4450s
     View PubMed
158. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Janne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.
     View PubMed
159. Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1106-11. Epub 2006 May 26.
     View PubMed
160. Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Adjei AA, Jett JR. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol. 2006 Jul; 1(6):556-63.
     View PubMed
161. Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology. 2006 Jun; 130(7):2130-44.
     View PubMed
162. Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Invest. 2006 Jun-Jul; 24 (4):382-9
     View PubMed
163. Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, Rowinsky EK. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2006 May 20; 24 (15):2252-60
     View PubMed
164. Dy GK, Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer. 2006 May; 7 Suppl 4:S145-9
     View PubMed
165. Adjei AA. Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol. 2006 May; 17 Suppl 5:v29-32.
     View PubMed
166. Adjei AA. Farnesyltransferase inhibitors. Update on Cancer Therapeutics. 2006; 1(1):17-23.
     
167. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006 Jan; 1(1):7-9.
     View PubMed
168. Barton DL, Loprinzi C, Atherton PJ, Kottschade L, Collins M, Carpenter P, Adjei A, Rummans TA, Shanafelt T, Christensen B, Sloan J. Dehydroepiandrosterone for the treatment of hot flashes: a pilot study. Support Cancer Ther. 2006 Jan 1; 3(2):91-7.
     View PubMed
169. Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B, Schild SE, Castillo R, Jett JR, North Central Cancer Treatment Group. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol. 2005 Dec 20; 23(36):9113-9.
     View PubMed
170. Dy GK, Mandrekar S, Peethambaram PP, Okuno SH, Croghan GC, Hanson LJ, Furth A, Adjei AA. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol. 2005 Dec; 56 (6):623-8 Epub 2005 July 06
     View PubMed
171. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta. 2005 Nov 25; 1756: (2)127-44.
     View PubMed
172. Adjei AA. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. Clin Lung Cancer. 2005 Nov; 7(3):221-3.
     View PubMed
173. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov; 16: (11)1811-6.
     View PubMed
174. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20; 24 (46):6861-9
     View PubMed
175. Adjei AA. Sequencing bortezomib with chemotherapy and targeted agents. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S56-8
     View PubMed
176. Loprinzi CL, Flynn PJ, Carpenter LA, Atherton P, Barton DL, Shanafelt TD, Rummans TA, Sloan JA, Adjei AA, Mincey BA, Fitch TR, Collins M. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med. 2005 Oct; 8(5):924-30.
     View PubMed
177. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res. 2005 Sep 15; 11 (18):6641-9
     View PubMed
178. Adjei AA. Targeting multiple signal transduction pathways in lung cancer. Clin Lung Cancer. 2005 Sep; 7 Suppl 1:S39-44
     View PubMed
179. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA, North Central Cancer Treatment Group, Mayo Clinic, Eli Lilly & Company. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 1; 23(25):5929-37.
     View PubMed
180. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005 Aug 15; 11 (16):5935-41
     View PubMed
181. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005 Aug 10; 23(23):5281-93. Epub 2005 Jul 11.
     View PubMed
182. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10; 23(23):5386-403. Epub 2005 Jun 27.
     View PubMed
183. Giordano KF, Jatoi A, Adjei AA, Creagan ET, Croghan G, Frytak S, Jett JR, Marks R, Molina J, Okuno S, Richardson RL. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer. 2005 Aug; 49(2):209-15. Epub 2005 Apr 13.
     View PubMed
184. Bruzek LM, Poynter JN, Kaufmann SH, Adjei AA. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyri din-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol. 2005 Aug; 68: (2)477-86.
     View PubMed
185. Tefferi A, Rajkumar SV, Adjei AA. Introduction to a cancer symposium for the practitioner. Mayo Clin Proc. 2005 Aug; 80(8):1085-6.
     View PubMed
186. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005 Jul; 128(1):452-62.
     View PubMed
187. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005 Jun 15; 103(12):2584-9.
     View PubMed
188. Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Mailliard JA, Krook JE, Deming RL, Adjei AA, Jatoi A, Jett JR. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005 Jun 1; 103(11):2349-54.
     View PubMed
189. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Jun; 55(6):522-30. Epub 2005 Mar 08.
     View PubMed
190. Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res. 2005 May 1; 11 (9):3410-6
     View PubMed
191. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. Ca: a Cancer Journal for Clinicians. 2005 May-Jun; 55(3):178-94.
     View PubMed
192. Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin Cancer Res. 2005 Mar 1; 11 (5):1877-83
     View PubMed
193. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005 Feb 20; 23(6):1078-87.
     View PubMed
194. Adjei AA. Farnesyltransferase inhibitors. Cancer Chemother Biol Response Modif. 2005; 22:123-33.
     View PubMed
195. Dy GK, Adjei AA. Obstacles and opportunities in the clinical development of targeted therapeutics. Prog Drug Res. 2005; 63:19-41.
     View PubMed
196. Ma CX, Adjei AA, Salavaggione OE, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei Weinshilboum RM. Human aromatase (CYP19) pharmacogenomics: gene resequencing and functional genomics. Cancer Res. 2005; 65:11071-82.
     View PubMed
197. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol. 2004 Dec 1; 22 (23):4810-5
     View PubMed
198. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004 Nov 15; 22(22):4456-62.
     View PubMed
199. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
     View PubMed
200. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4276s-4280s.
     View PubMed
201. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 1; 103(9):3271-7. Epub 2004 Jan 15.
     View PubMed
202. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004 Apr; 5 Suppl 2:S51-5
     View PubMed
203. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol. 2004 Feb; 31(1 Suppl 1):28-39.
     View PubMed
204. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 2003 Dec 15; 102 (13):4512-9 Epub 2003 Aug 14
     View PubMed
205. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003 Oct 15; 21 (20):3761-9 Epub 2003 Sept 08
     View PubMed
206. Adjei AA. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. Lung Cancer. 2003 Aug; 41(Suppl 1):S55-S62.
     View PubMed
207. Shanafelt T, Adjei A, Meyskens FL. When your favorite patient relapses: Physician grief and well-being in the practice of oncology. J Clin Oncol. 2003 Jul 1; 21(13):2616-9.
     View PubMed
208. Molina JR, Adjei AA. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul; 5(1):21-7.
     View PubMed
209. Adjei AA, Rowinsky EK. Novel anticancer agents in clinical development. Cancer Biol Ther. 2003 Jul-Aug; 2 (4 Suppl 1):S5-15
     View PubMed
210. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003 Jul; 9 (7):2520-6
     View PubMed
211. Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003 May 01; 21: (9)1760-6.
     View PubMed
212. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May; 9(5):1639-47.
     View PubMed
213. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr; 3(2):145-56.
     View PubMed
214. Dees EC, Rowinsky EK, Noe DA, O'Reilly S, Adjei AA, Elza-Brown K, Donehower RC. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Invest New Drugs. 2003 Feb; 21(1):75-84.
     View PubMed
215. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan; 9(1):115-23.
     View PubMed
216. Adjei AA. Farnesyltransferase inhibitors. Cancer Chemotherapy & Biological Response Modifiers. 2003; 21:127-44.
     View PubMed
217. Adjei AA. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. Semin Oncol. 2002 Dec; 29: (6 Suppl 18)30-4.
     View PubMed
218. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002 Nov; 77(11):1207-18.
     View PubMed
219. Goldberg RM, Kaufmann SH, Atherton P, Sloan JA, Adjei AA, Pitot HC, Alberts SR, Rubin J, Miller LL, Erlichman C. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Ann Oncol. 2002 Oct; 13 (10):1674-80
     View PubMed
220. Ghobrial IM, Adjei AA. Inhibitors of the ras oncogene as therapeutic targets. Hematol Oncol Clin North Am. 2002 Oct; 16 (5):1065-88
     View PubMed
221. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer. 2002 Sep; 38 (13):1685-700
     View PubMed
222. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol. 2002 Aug; 13 (8):1225-35
     View PubMed
223. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs. 2002 Aug; 20 (3):297-304
     View PubMed
224. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part II. J Clin Oncol. 2002 Jul 1; 20: (13)3016-28.
     View PubMed
225. Dy GK, Adjei AA. The role of farnesyltransferase inhibitors in lung cancer therapy. Clin Lung Cancer. 2002 Jul; 4 (1):57-62
     View PubMed
226. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol. 2002 Jun 15; 20: (12)2881-94.
     View PubMed
227. Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol. 2002 Jun; 25 (3):308-12
     View PubMed
228. Adjei AA. Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes. Clin Breast Cancer. 2002 May; 3 Suppl 1:21-3
     View PubMed
229. Adjei AA. Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr; 29: (2 Suppl 5)50-3.
     View PubMed
230. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002 Mar 15; 20: (6)1683-91.
     View PubMed
231. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res. 2002 Mar; 8 (3):712-7
     View PubMed
232. Adjei AA. Blocking oncogene ras signaling for cancer therapy. J Natl Cancer Inst. 2002; 94(13):1032.
     
233. Dy GK, Adjei AA. Farnesyltransferase inhibitors in breast cancer therapy. Cancer Invest. 2002; 20 Suppl 2:30-7.
     View PubMed
234. Adjei AA. Farnesyltransferase inhibitors. Cancer Chemotherapy & Biological Response Modifiers. 2002; 20:151-67.
     View PubMed
235. Dy GK, Haluska P, Adjei AA. Novel pharmacological agents in clinical development for solid tumours. Expert Opin Investig Drugs. 2001 Dec; 10: (12)2059-88.
     View PubMed
236. Adjei AA. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec; 34 Suppl 4:S103-5.
     View PubMed
237. Adjei AA. Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des. 2001 Nov; 7 (16):1581-94
     View PubMed
238. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001 Nov; 13(6):470-6.
     View PubMed
239. Adjej AA. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy. Drugs Future. 2001 Nov; 26(11):1087-92.
     
240. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer. 2001 Aug 17; 85 (4):484-9
     View PubMed
241. Daniels GA, Adjei AA. Advances in systemic therapy of small cell cancer of the lung. Expert Rev Anticancer Ther. 2001 Aug; 1: (2)211-21.
     View PubMed
242. Bekele L, Vidal Vazquez M, Adjei AA. Systemic chemotherapy in patients with renal failure. Am J Clin Oncol. 2001 Aug; 24 (4):382-4
     View PubMed
243. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001 Jul 18; 93 (14):1062-74
     View PubMed
244. Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001 May; 7: (5)1438-45.
     View PubMed
245. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol. 2001 May; 12 (5):701-7
     View PubMed
246. Alberts SR, Erlichman C, Sloan J, Sloan J, Okuno SH, Burch PA, Rubin J, Pitot HC, Goldberg RM, Adjei AA, Atherton PJ, Kaufmann SH. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Ann Oncol. 2001 May; 12 (5):627-31
     View PubMed
247. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001 Mar; 12 (3):389-95
     View PubMed
248. Xu Z, Wood TC, Adjei AA, Weinshilboum RM. Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation. Drug Metab Dispos. 2001 Feb; 29 (2):172-8
     View PubMed
249. Adjei AA. Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb; 15(2 Suppl 3):34-7.
     View PubMed
250. Haluska P, Adjei AA. Receptor tyrosine kinase inhibitors. Curr Opin Investig Drugs. 2001 Feb; 2 (2):280-6
     View PubMed
251. Adjei AA. Farnesyltransferase inhibitors. Cancer Chemother Biol Response Modif. 2001; 19:149-64.
     View PubMed
252. Adjei AA. Protein farnesyl transferase as a target for the development of anticancer drugs. Drugs Future. 2000 Oct; 25(10):1069-1079.
     
253. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol. 2000 Oct; 11 (10):1335-41
     View PubMed
254. Adjei AA. Management of small cell cancer of the lung. Curr Opin Pulm Med. 2000 Jul; 6(4):384-90.
     
255. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res. 2000 Jun; 6 (6):2236-44
     View PubMed
256. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000 Jun; 6: (6)2318-25.
     View PubMed
257. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000 Apr 01; 60: (7)1871-7.
     View PubMed
258. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000 Apr; 18: (8)1748-57.
     View PubMed
259. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol. 2000 Mar; 18 (5):1116-23
     View PubMed
260. Adjei AA. Signal transduction pathway targets for anticancer drug discovery. Curr Pharm Des. 2000 Mar; 6 (4):361-78
     View PubMed
261. Adjei AA, Argiris A, Murren JR. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Oct; 26 (5 Suppl 16):32-40; discussion 41-2
     View PubMed
262. Adjei AA. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol. 1999 Sep; 48 (3):265-77
     View PubMed
263. Adjei AA, Marks RS, Bonner JA. Current guidelines for the management of small cell lung cancer. Mayo Clin Proc. 1999 Aug; 74(8):809-16.
     View PubMed
264. Adjei AA, Erlichman C. A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer. Semin Oncol. 1999 Apr; 26(2 Suppl 6):94-8.
     View PubMed
265. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999 Apr; 10 (4):413-9
     View PubMed
266. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999 Mar; 5 (3):525-31
     View PubMed
267. Adjei AA. Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs. 1999; 17 (1):43-8
     View PubMed
268. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999 Jan; 17: (1)409-22.
     View PubMed
269. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar; 4 (3):683-91
     View PubMed
270. Rajkumar SV, Adjei AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev. 1998 Feb; 24 (1):35-53
     View PubMed
271. Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res. 1997 May; 3 (5):761-70
     View PubMed
272. Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorius SE, Noe DA, Hohneker JA, Rowinsky EK. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol. 1996; 14(12):3085-96.
     View PubMed
273. Rowinsky EK, Adjei AA, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory leukemia. J Clin Oncol. 1994; 12:2193-2203.
     View PubMed
274. Adjei AA, Dagnino L, Wong MM, Paterson AR. Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine. Cancer Chemotherapy & Pharmacology. 1992; 31(1):71-5.
     View PubMed
275. Adjei AA, Kuznetsov GP. [Should the therapist know how to distinguish only "the iamb from chorea"? (by way of a discussion)]. Ter Arkh. 1989; 61: (11)153-5.
     View PubMed